AEHR · XBRL financial data

Aehr Test Systems financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (AEHR's year ends in late May)

In thousands of dollars	FY 2021May 31, 2021	FY 2022May 31, 2022	FY 2023May 31, 2023	FY 2024May 31, 2024	FY 2025May 30, 2025	FY 2026May 29, 2026
Revenue	16,600	50,829	64,961	66,218	58,968	50,001
Revenue from contracts with customers	16,600	50,829	64,961	66,218	58,968	50,001
Cost of revenue	10,568	27,164	32,215	33,675	35,035	32,350
Gross profit	6,032	23,665	32,746	32,543	23,933	17,651
Research and development	3,652	5,818	7,134	8,719	10,463	12,633
Selling, general and administrative	6,562	10,047	12,237	13,746	18,283	19,161
Total operating expenses	10,214	15,865	19,371	22,465	29,610	31,800
Operating income (loss)	(4,182)	7,800	13,375	10,078	(5,677)	(14,149)
Other income (expense)	(162)	30	(3)	(8)	(15)	1,052
Income tax expense (benefit)	(177)	(91)	60	(20,698)	(381)	(4,610)
Net income (loss)	(2,027)	9,450	14,557	33,156	(3,910)	(7,126)
Earnings per share, basic USD per share	(0.09)	0.36	0.52	1.15	(0.13)	(0.23)
Earnings per share, diluted USD per share	(0.09)	0.34	0.50	1.12	(0.13)	(0.23)
Weighted average shares, basic thousands of shares	23	26,014	27,785	28,818	29,581	30,669
Weighted average shares, diluted thousands of shares	23	27,774	29,215	29,617	29,581	30,669

Fiscal years (AEHR's year ends in late May)

In thousands of dollars	FY 2021May 31, 2021	FY 2022May 31, 2022	FY 2023May 31, 2023	FY 2024May 31, 2024	FY 2025May 30, 2025	FY 2026May 29, 2026
Cash and cash equivalents	4,582	31,484	30,054	49,159	24,529	116,358
Short-term investments	—	—	17,853	0	—	—
Accounts receivable	5,202	12,859	—	—	—	—
Inventory	8,849	15,051	23,908	37,470	41,997	41,354
Prepaid and other current assets	551	613	621	1,423	8,061	9,263
Total current assets	19,184	60,007	89,030	97,848	88,778	184,448
Property and equipment, net	677	1,203	2,759	3,253	8,969	8,940
Right-of-use asset	1,606	917	6,123	5,734	9,601	8,901
Goodwill	—	—	—	0	10,719	10,719
Total assets	21,665	62,328	98,143	127,912	148,508	246,694
Accounts payable	2,893	4,195	9,206	5,332	6,728	6,754
Accrued liabilities	2,163	3,610	4,143	3,366	—	—
Current portion of long-term debt	1,679	0	—	—	—	—
Total current liabilities	9,061	11,014	16,308	10,508	15,638	17,855
Long-term debt	0	—	—	—	—	—
Lease liability, non-current	1,007	212	6,163	5,732	9,921	9,256
Total liabilities	10,216	11,339	22,543	16,319	25,637	27,183
Accumulated deficit	(76,313)	(66,863)	(52,306)	(19,150)	(23,060)	(30,186)
Total stockholders' equity	11,449	50,989	75,600	111,593	122,871	219,511
Total liabilities and equity	21,665	62,328	98,143	127,912	148,508	246,694
Common shares outstanding (cover page) thousands of shares	24,169	27,344	28,755	29,007	29,915	32,620

Fiscal years (AEHR's year ends in late May)

In thousands of dollars	FY 2021May 31, 2021	FY 2022May 31, 2022	FY 2023May 31, 2023	FY 2024May 31, 2024	FY 2025May 30, 2025	FY 2026May 29, 2026
Net income (loss)	(2,027)	9,450	14,557	33,156	(3,910)	(7,126)
Stock-based compensation	1,101	3,006	2,748	2,518	5,162	6,761
Net cash from operating activities	(2,701)	1,508	10,011	1,756	(7,400)	(3,310)
Purchases of property and equipment	227	416	1,362	749	4,992	2,066
Net cash from investing activities	(227)	(416)	(18,656)	17,251	(16,067)	(3,867)
Proceeds from issuing common stock	580	3,560	2,562	1,807	1,409	2,200
Proceeds from issuing equity	0	24,030	6,820	—	—	—
Proceeds from long-term debt	0	0	—	—	—	—
Net cash from financing activities	1,960	25,761	7,322	139	625	97,211
Net change in cash	(851)	26,902	(1,360)	19,105	(22,829)	90,028

SIC 3825 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3825 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Aehr Test Systems	116,358	18,835*	1,832*	32.6M	—	Q4 FY26 10-KMay 29, 2026
Transcat	5,758	97,090	10,148*	9.4M	—	Q2 FY27 10-QSep 26, 2026
EyePoint	110,458	507	(62,348)*	86.2M	2.9 quarters	Q2 FY26 10-QJun 30, 2026
Allient	39,646	164,399	1,957*	17.0M	—	Q3 FY26 10-QSep 30, 2026
Cohu	272,303	172,956	5,600*	47.3M	—	Q3 FY26 10-QSep 26, 2026
Cytek Biosciences	66,806	53,229	not reported	130.8M	—	Q3 FY26 10-QSep 30, 2026
Senseonics Holdings	44,753	14,483	(30,138)*	52.9M	4.7 quarters	Q2 FY26 10-QJun 30, 2026
Pacific Biosciences of California	61,003	39,007	(35,583)*	310.8M	6.7 quarters	Q2 FY26 10-QJun 30, 2026
Mesa Laboratories	30,695	60,138	14,736	5.6M	—	Q1 FY27 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.